Cipla And Alvotech Prime Emerging Markets Push With Adalimumab Deal

Cipla has firmed up a commercialization deal with Alvotech for the Icelandic developer’s high-concentration version of AbbVie’s Humira, continuing to use the licensing approach to expand its biosimilar franchise in emerging markets.

Business Puzzle

More from Biosimilars

More from Products